Louise Grybowicz

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Helena Earl, Louise Hiller, Janet Dunn et al. · The Lancet Oncology · 2015 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

Helena Earl, Louise Hiller, Janet Dunn et al. · Annals of Oncology · 2017 · 54 citations · Full text

Medicine, Oncology, Pharmacology +15

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Jean Abraham, Karen Pinilla, Alimu Dayimu et al. · Nature · 2024 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility

Shadi Basyuni, Laura Heskin, Andrea Degasperi et al. · Nature Communications · 2024 · 34 citations · Full text

Life Sciences, Oncology, Pathology +17

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

Jeremy Thomas, Elena Provenzano, Louise Hiller et al. · Modern Pathology · 2017 · 17 citations · Full text

Medicine, Oncology, Pathology +12